Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069333 | PMC |
| http://dx.doi.org/10.4103/sajc.sajc_231_17 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
Cureus
June 2020
Internal Medicine, Yale University School of Medicine, New Haven, USA.
Immune checkpoint inhibitor (CPI) therapy is approved for the treatment of many cancers. As its use becomes more prevalent, sequential trials with different CPIs as monotherapy or combination therapy will become more common. It is thought that the increased cumulative dose of CPIs over multiple trials increases the risk of immune-related adverse events (irAEs).
View Article and Find Full Text PDFFrontline immunotherapy for NSCLC - the tale of the tail.
Nat Rev Clin Oncol
February 2020
Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
Ipilimumab: A tale of twists and turns.
South Asian J Cancer
January 2018
Pharm-Olam International Private Limited, Raleigh, North Carolina, USA.
A tale of two tumours and a plea for progress.
Lancet Oncol
February 2012
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!